1695-6,5-Hydroxyindoleacetate [Mass/time] in 24 hour Urine
31203-3,5-Hydroxyindoleacetate [Mass/volume] in 24 hour Urine
1692-3,5-Hydroxyindoleacetate [Mass/volume] in Cerebral spinal fluid
1693-1,5-Hydroxyindoleacetate [Mass/volume] in Serum or Plasma
1694-9,5-Hydroxyindoleacetate [Mass/volume] in Urine
72820-4,5-Hydroxyindoleacetate [Mass/volume] in Urine by Confirmatory method
14573-0,5-Hydroxyindoleacetate [Moles/time] in 24 hour Urine
25971-3,5-Hydroxyindoleacetate [Moles/volume] in 24 hour Urine
47544-2,5-Hydroxyindoleacetate [Moles/volume] in Cerebral spinal fluid
74769-1,5-Hydroxyindoleacetate [Moles/volume] in Platelet rich plasma
50149-4,5-Hydroxyindoleacetate [Moles/volume] in Serum or Plasma
15009-4,5-Hydroxyindoleacetate [Moles/volume] in Urine
12172-3,5-Hydroxyindoleacetate [Presence] in 24 hour Urine
48168-9,5-Hydroxyindoleacetate [Presence] in Urine
11145-0,5-Hydroxyindoleacetate/​Creatinine [Mass Ratio] in Urine
44909-0,5-Hydroxyindoleacetate and Creatinine [Interpretation] in Urine
10459-6,Alpha-1-Fetoprotein Ag [Presence] in Tissue by Immune stain
11207-8,Alpha-1-Fetoprotein [Mass/volume] in Body fluid
1833-3,Alpha-1-Fetoprotein [Mass/volume] in Cerebral spinal fluid
54348-8,Alpha-1-Fetoprotein [Mass/volume] in Cord blood
49761-0,Alpha-1-Fetoprotein [Mass/volume] in Peritoneal fluid
49762-8,Alpha-1-Fetoprotein [Mass/volume] in Pleural fluid
1834-1,Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma
83073-7,Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma by Immunoassay
19173-4,Alpha-1-Fetoprotein [Moles/volume] in Pleural fluid
19177-5,Alpha-1-Fetoprotein [Moles/volume] in Serum or Plasma
31993-9,Alpha-1-Fetoprotein [Presence] in Serum or Plasma
44910-8,Alpha-1-Fetoprotein [Units/volume] in Body fluid
59564-5,Alpha-1-Fetoprotein [Units/volume] in Cerebral spinal fluid
19172-6,Alpha-1-Fetoprotein [Units/volume] in Pleural fluid
19176-7,Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma
83072-9,Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma by Immunoassay
41274-2,Alpha-1-Fetoprotein interpretation in Serum or Plasma
49246-2,Alpha-1-Fetoprotein interpretation in Serum or Plasma Narrative
49585-3,Alpha-1-Fetoprotein multiple of the median cutoff [Multiple of the median] in Serum or Plasma
53962-7,Alpha-1-fetoprotein.tumor marker [Mass/volume] in Serum or Plasma
53960-1,Alpha-1-fetoprotein.tumor marker [Moles/volume] in Serum or Plasma
53961-9,Alpha-1-fetoprotein.tumor marker [Units/volume] in Serum or Plasma
10873-8,Beta-2-Microglobulin [Mass/time] in 24 hour Urine
54356-1,Beta-2-Microglobulin [Mass/volume] in 24 hour Urine
48166-3,Beta-2-Microglobulin [Mass/volume] in Body fluid
1951-3,Beta-2-Microglobulin [Mass/volume] in Cerebral spinal fluid
49081-3,Beta-2-Microglobulin [Mass/volume] in Dialysis fluid
88711-7,Beta-2-Microglobulin [Mass/volume] in Peritoneal dialysis fluid
59217-0,Beta-2-Microglobulin [Mass/volume] in Peritoneal fluid
59218-8,Beta-2-Microglobulin [Mass/volume] in Pleural fluid
1952-1,Beta-2-Microglobulin [Mass/volume] in Serum or Plasma
87708-4,Beta-2-Microglobulin [Mass/volume] in Serum or Plasma --post dialysis
83078-6,Beta-2-Microglobulin [Mass/volume] in Serum or Plasma by Immunoassay
1953-9,Beta-2-Microglobulin [Mass/volume] in Urine
83077-8,Beta-2-Microglobulin [Mass/volume] in Urine by Immunoassay
56662-0,Beta-2-Microglobulin [Moles/time] in 24 hour Urine
50824-2,Beta-2-Microglobulin [Moles/volume] in 24 hour Urine
39458-5,Beta-2-Microglobulin [Moles/volume] in Body fluid
32301-4,Beta-2-Microglobulin [Moles/volume] in Cerebral spinal fluid
14626-6,Beta-2-Microglobulin [Moles/volume] in Serum
76484-5,Beta-2-Microglobulin [Moles/volume] in Serum or Plasma
32302-2,Beta-2-Microglobulin [Moles/volume] in Urine
43919-0,Beta-2-Microglobulin [Presence] in Cerebral spinal fluid
43818-4,Beta-2-Microglobulin [Presence] in Serum
43819-2,Beta-2-Microglobulin [Presence] in Urine
83076-0,Beta-2-Microglobulin [Units/volume] in Serum or Plasma by Immunoassay
83079-4,Beta-2-Microglobulin [Units/volume] in Urine by Immunoassay
10467-9,Beta-2-Microglobulin amyloid Ag [Presence] in Tissue by Immune stain
54355-3,Beta-2-Microglobulin in CSF/Beta-2-Microglobulin in serum
56786-7,Beta-2-Microglobulin.tumor marker [Mass/volume] in Serum
2006-5,Cancer Ag 125 [Presence] in Serum or Plasma
48677-9,Cancer Ag 125 [Presence] in Tissue by Immune stain
11210-2,Cancer Ag 125 [Units/volume] in Body fluid
15156-3,Cancer Ag 125 [Units/volume] in Body fluid by Dilution
50775-6,Cancer Ag 125 [Units/volume] in Cerebral spinal fluid
68923-2,Cancer Ag 125 [Units/volume] in Pericardial fluid
59040-6,Cancer Ag 125 [Units/volume] in Peritoneal dialysis fluid
40618-1,Cancer Ag 125 [Units/volume] in Peritoneal fluid
19165-0,Cancer Ag 125 [Units/volume] in Pleural fluid
10334-1,Cancer Ag 125 [Units/volume] in Serum or Plasma
15157-1,Cancer Ag 125 [Units/volume] in Serum or Plasma by Dilution
83082-8,Cancer Ag 125 [Units/volume] in Serum or Plasma by Immunoassay
2007-3,Cancer Ag 15-3 [Presence] in Serum or Plasma
29153-4,Cancer Ag 15-3 [Units/volume] in Body fluid
50776-4,Cancer Ag 15-3 [Units/volume] in Cerebral spinal fluid
50777-2,Cancer Ag 15-3 [Units/volume] in Pericardial fluid
50778-0,Cancer Ag 15-3 [Units/volume] in Peritoneal fluid
19186-6,Cancer Ag 15-3 [Units/volume] in Pleural fluid
6875-9,Cancer Ag 15-3 [Units/volume] in Serum or Plasma
83083-6,Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay
2009-9,Cancer Ag 19-9 [Presence] in Serum or Plasma
26924-1,Cancer Ag 19-9 [Units/volume] in Body fluid
50779-8,Cancer Ag 19-9 [Units/volume] in Cerebral spinal fluid
50780-6,Cancer Ag 19-9 [Units/volume] in Pericardial fluid
50781-4,Cancer Ag 19-9 [Units/volume] in Peritoneal fluid
19163-5,Cancer Ag 19-9 [Units/volume] in Pleural fluid
24108-3,Cancer Ag 19-9 [Units/volume] in Serum or Plasma
83084-4,Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
2012-3,Cancer Ag 27-29 [Presence] in Serum or Plasma
50782-2,Cancer Ag 27-29 [Units/volume] in Cerebral spinal fluid
19187-4,Cancer Ag 27-29 [Units/volume] in Pleural fluid
17842-6,Cancer Ag 27-29 [Units/volume] in Serum or Plasma
12515-3,Carcinoembryonic Ag [Mass/volume] in Body fluid
2037-0,Carcinoembryonic Ag [Mass/volume] in Cerebral spinal fluid
40621-5,Carcinoembryonic Ag [Mass/volume] in Pericardial fluid
40622-3,Carcinoembryonic Ag [Mass/volume] in Peritoneal fluid
19169-2,Carcinoembryonic Ag [Mass/volume] in Pleural fluid
2038-8,Carcinoembryonic Ag [Mass/volume] in Semen
2039-6,Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
83085-1,Carcinoembryonic Ag [Mass/volume] in Serum or Plasma by Immunoassay
19170-0,Carcinoembryonic Ag [Moles/volume] in Pleural fluid
19167-6,Carcinoembryonic Ag [Moles/volume] in Serum or Plasma
10469-5,Carcinoembryonic Ag [Presence] in Tissue by Immune stain
19168-4,Carcinoembryonic Ag [Units/volume] in Pleural fluid
10560-1,Carcinoembryonic Ag [Units/volume] in Semen
19166-8,Carcinoembryonic Ag [Units/volume] in Serum or Plasma
85337-4,Estrogen receptor Ag [Presence] in Breast cancer specimen by Immune stain
40556-3,Estrogen receptor Ag [Presence] in Tissue by Immune stain
16112-5,Estrogen receptor [Interpretation] in Tissue
14130-9,Estrogen receptor [Moles/mass] in Tissue
85310-1,Estrogen receptor fluorescence intensity [Type] in Breast cancer specimen by Immune stain
10480-2,Estrogen+Progesterone receptor Ag [Presence] in Tissue by Immune stain
48676-1,HER2 [Interpretation] in Tissue
32996-1,HER2 [Mass/volume] in Serum
42914-2,HER2 [Mass/volume] in Serum by Immunoassay
85318-4,HER2 [Presence] in Breast cancer specimen by FISH
85319-2,HER2 [Presence] in Breast cancer specimen by Immune stain
51981-9,HER2 [Presence] in Serum by Immunoassay
31150-6,HER2 [Presence] in Tissue by FISH
72383-3,HER2 [Presence] in Tissue by Immunoassay
72382-5,HER2 [Units/volume] in Tissue by Immunoassay
18474-7,HER2 Ag [Presence] in Tissue by Immune stain
49683-6,HER2 gene copy number/Chromosome 17 copy number in Tissue by FISH
74860-8,HER2 gene copy number/nucleus in Tissue by FISH
74885-5,HER2 panel - Tissue by FISH
83054-7,PD-L1 by clone 22C3 [Interpretation] in Tissue by Immune stain Narrative
83052-1,PD-L1 by clone 22C3 [Presence] in Tissue by Immune stain
83056-2,PD-L1 by clone 28-8 [Interpretation] in Tissue by Immune stain Narrative
83055-4,PD-L1 by clone 28-8 [Presence] in Tissue by Immune stain
83057-0,PD-L1 by clone SP142 [Presence] in Tissue by Immune stain
83053-9,Cells.programmed cell death ligand 1/100 viable tumor cells in Tissue by Immune stain. (source: LOINC)
85339-0,Progesterone receptor Ag [Presence] in Breast cancer specimen by Immune stain
40557-1,Progesterone receptor Ag [Presence] in Tissue by Immune stain
16113-3,Progesterone receptor [Interpretation] in Tissue
10861-3,Progesterone receptor [Mass/mass] in Tissue
31207-4,Progesterone receptor [Moles/mass] in Tissue
85331-7,Progesterone receptor fluorescence intensity [Type] in Breast cancer specimen by Immune stain
47738-0,Prostate specific Ag [Mass/volume] in Body fluid
59230-3,Prostate specific Ag [Mass/volume] in Cerebral spinal fluid
59223-8,Prostate specific Ag [Mass/volume] in Peritoneal fluid
59221-2,Prostate specific Ag [Mass/volume] in Pleural fluid
19199-9,Prostate specific Ag [Mass/volume] in Semen
2857-1,Prostate specific Ag [Mass/volume] in Serum or Plasma
35741-8,Prostate specific Ag [Mass/volume] in Serum or Plasma by Detection limit <= 0.01 ng/mL
83112-3,Prostate specific Ag [Mass/volume] in Serum or Plasma by Immunoassay
34611-4,Prostate specific Ag [Mass/volume] in Urine
19200-5,Prostate specific Ag [Moles/volume] in Semen
19197-3,Prostate specific Ag [Moles/volume] in Serum or Plasma
10508-0,Prostate specific Ag [Presence] in Tissue by Immune stain
19198-1,Prostate specific Ag [Units/volume] in Semen
19195-7,Prostate specific Ag [Units/volume] in Serum or Plasma
15325-4,Prostate specific Ag/Prostate volume calculated
15323-9,Prostate specific Ag/Prostate volume calculated from height, width and length
15324-7,Prostate specific Ag/Prostate volume calculated from planimetry
14228-1,Cells.estrogen receptor/100 cells in Tissue by Immune stain
85329-1,Cells.estrogen receptor/100 cells in Breast cancer specimen by Immune stain
14230-7,Cells.progesterone receptor/100 cells in Tissue by Immune stain
85325-9,Cells.progesterone receptor/100 cells in Breast cancer specimen by Immune stain
79417-2,PMS2 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA
79419-8,PMS2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method
79570-8,MLH1+MSH2+MSH6+PMS2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method
81694-2,Mismatch repair endonuclease PMS2 [Presence] in Cancer specimen by Immune stain
32630-6,MSH2 gene+MLH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
38536-9,MLH1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method
41086-0,MLH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
58010-0,MSH2 gene+MLH1 gene+MSH6 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
58416-9,MLH1 gene methylation [Presence] in Blood or Tissue by Molecular genetics method
76063-7,MSH2 gene+MLH1 gene+MSH6 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method
79416-4,MLH1 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA
81691-8,DNA mismatch repair protein Mlh1 [Presence] in Cancer specimen by Immune stain
92676-6,MLH1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method
97760-3,MLH1 gene methylation analysis in Blood by Molecular genetics method
97761-1,MLH1 gene methylation analysis in Tumor by Molecular genetics method
38550-0,MSH2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method
41084-5,MSH2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
79415-6,MSH2 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA
81692-6,DNA mismatch repair protein Msh2 [Presence] in Cancer specimen by Immune stain
89039-2,MSH2 gene deletion+duplication and full mutation analysis and EPCAM gene exons 8 and 9 deletion and duplication mutation analysis in Blood or Tissue by Molecular genetics method
92675-8,MSH2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method
38906-4,MSH6 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method
38921-3,MSH6 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
79414-9,MSH6 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA
81693-4,DNA mismatch repair protein Msh6 [Presence] in Cancer specimen by Immune stain
95774-6,MSH6 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method
81708-0,Microsatellite markers exhibiting instability/Microsatellite instability markers assessed in Cancer specimen
43368-0,Microsatellite instability [Identifier] in Tissue by Molecular genetics method Nominal
62862-8,Microsatellite instability [Presence] in Tissue by Immune stain
81695-9,Microsatellite instability [Interpretation] in Cancer specimen Qualitative
81696-7,Microsatellite instability markers assessed [#] in Cancer specimen
81697-5,Microsatellite instability marker BAT25 in Cancer specimen Qualitative
81698-3,Microsatellite instability marker BAT26 in Cancer specimen Qualitative
81699-1,Microsatellite instability marker NR21 in Cancer specimen Qualitative
81700-7,Microsatellite instability marker NR24 in Cancer specimen Qualitative
81701-5,Microsatellite instability marker MONO27 in Cancer specimen Qualitative
81702-3,Microsatellite instability marker D2S123 in Cancer specimen Qualitative
81703-1,Microsatellite instability marker D5S346 in Cancer specimen Qualitative
81704-9,Microsatellite instability marker D17S250 in Cancer specimen Qualitative
81709-8,Microsatellite markers exhibiting instability [#] in Cancer specimen
81711-4,Microsatellite instability marker panel - Cancer specimen
11080-9,HIV 2 p53 Ab [Presence] in Serum by Immunoblot
12876-9,HIV 1 p53 Ab [Presence] in Serum by Immunoblot
14026-9,HTLV I+II p53 Ab [Presence] in Serum by Immunoblot
14223-2,HTLV I p53 Ab [Presence] in Serum
14229-9,P53 protein Ag [Presence] in Tissue by Immune stain
31149-8,P53 protein Ag/100 cells in Tissue by Immune stain
43295-5,HTLV I+II p53 Ab [Presence] in Serum
89006-1,p53 Ab [Units/volume] in Serum or Plasma by Immunoassay
97049-1,p53 Ab [Mass/volume] in Serum or Plasma by Immunoassay